Patents by Inventor Jamie Mann

Jamie Mann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AUTOLOGOUS AND ALLOGENIC HIV-1 PROTEINS FOR THE TREATMENT OF LATENT HIV-1 INFECTION
    Publication number: 20230390377
    Abstract: A method of reducing a latent HIV-specific memory-CD4+ T cell pool in a subject includes administering to the subject at least one HIV-1 protein and a pharmaceutically acceptable carrier, wherein the at least one HIV-1 protein is derived from an allogenic infecting HIV-1 virus, and wherein the HIV-1 protein stimulates latent HIV-specific memory CD4+ T cells to induce latent HIV-1 replication resulting in HIV-specific memory-CD4+ T cell death in the subject.
    Type: Application
    Filed: March 7, 2023
    Publication date: December 7, 2023
    Inventors: Eric J. Arts, Jamie Mann
  • Autologous and allogenic HIV-1 proteins for the treatment of latent HIV-1 infection
    Patent number: 11596682
    Abstract: A method of reducing a latent HIV-specific memory-CD4+ T cell pool in a subject includes administering to the subject at least one HIV-1 protein and a pharmaceutically acceptable carrier, wherein the at least one HIV-1 protein is derived from an allogenic infecting HIV-1 virus, and wherein the HIV-1 protein stimulates latent HIV-specific memory CD4+ T cells to induce latent HIV-1 replication resulting in HIV-specific memory-CD4+ T cell death in the subject.
    Type: Grant
    Filed: December 8, 2020
    Date of Patent: March 7, 2023
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Eric J. Arts, Jamie Mann
  • AUTOLOGOUS AND ALLOGENIC HIV-1 PROTEINS FOR THE TREATMENT OF LATENT HIV-1 INFECTION
    Publication number: 20210170015
    Abstract: A method of reducing a latent HIV-specific memory-CD4+ T cell pool in a subject includes administering to the subject at least one HIV-1 protein and a pharmaceutically acceptable carrier, wherein the at least one HIV-1 protein is derived from an allogenic infecting HIV-1 virus, and wherein the HIV-1 protein stimulates latent HIV-specific memory CD4+ T cells to induce latent HIV-1 replication resulting in HIV-specific memory-CD4+ T cell death in the subject.
    Type: Application
    Filed: December 8, 2020
    Publication date: June 10, 2021
    Inventors: Eric J. Arts, Jamie Mann
  • Autologous and allogenic HIV-1 proteins for the treatment of latent HIV-1 infection
    Patent number: 10857223
    Abstract: A method of reducing a latent HIV-specific memory-CD4+ T cell pool in a subject includes administering to the subject at least one HIV-1 protein and a pharmaceutically acceptable carrier, wherein the at least one HIV-1 protein is derived from an allogenic infecting HIV-1 virus, and wherein the HIV-1 protein stimulates latent HIV-specific memory CD4+ T cells to induce latent HIV-1 replication resulting in HIV-specific memory-CD4+ T cell death in the subject.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: December 8, 2020
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Eric J. Arts, Jamie Mann